DIH Holding US (OTCMKTS:DHAI – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.
Risk and Volatility
DIH Holding US has a beta of -6.5, indicating that its share price is 750% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for DIH Holding US and NovoCure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DIH Holding US | 1 | 0 | 0 | 0 | 1.00 |
| NovoCure | 1 | 4 | 2 | 0 | 2.14 |
Earnings and Valuation
This table compares DIH Holding US and NovoCure”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DIH Holding US | $62.86 million | 0.00 | -$8.68 million | ($4.94) | -0.00 |
| NovoCure | $655.35 million | 2.88 | -$136.23 million | ($1.30) | -12.48 |
DIH Holding US has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than DIH Holding US, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares DIH Holding US and NovoCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DIH Holding US | N/A | N/A | N/A |
| NovoCure | -21.25% | -44.00% | -15.85% |
Insider and Institutional Ownership
27.8% of DIH Holding US shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 27.0% of DIH Holding US shares are owned by insiders. Comparatively, 6.6% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
NovoCure beats DIH Holding US on 8 of the 14 factors compared between the two stocks.
About DIH Holding US
DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Receive News & Ratings for DIH Holding US Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIH Holding US and related companies with MarketBeat.com's FREE daily email newsletter.
